Rabbit Polyclonal Cdk8 Antibody

中文名： Cdk8抗体
别名： CDK8; Cyclin-dependent kinase 8; Cell division protein kinase 8; Mediator complex subunit CDK8; Mediator of RNA polymerase II transcription subunit CDK8; Protein kinase K35

货号: IPDX43059

Price： ￥1180

50μl 100μl

数量：

大包装询价

验证与应用

应用及物种

WB	咨询技术	Human,Mouse,Rat
IF	咨询技术	Human,Mouse,Rat
IHC	1/100-1/300	Human,Mouse,Rat
ICC	技术咨询	Human,Mouse,Rat
FCM	咨询技术	Human,Mouse,Rat
Elisa	1/10000	Human,Mouse,Rat

产品详情

Aliases	CDK8; Cyclin-dependent kinase 8; Cell division protein kinase 8; Mediator complex subunit CDK8; Mediator of RNA polymerase II transcription subunit CDK8; Protein kinase K35
Entrez GeneID	1024;
WB Predicted band size	53kDa
Host/Isotype	Rabbit IgG
Antibody Type	Primary antibody
Storage	Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species Reactivity	Human,Mouse
Immunogen	Synthesized peptide derived from the N-terminal region of human Cdk8.
Formulation	Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol.

+ +

Western Blot analysis of 293 cells using Cdk8 Polyclonal Antibody

参考文献

以下是关于CDK8抗体的3篇参考文献及其摘要概述：

1. **"CDK8 is a colorectal cancer oncogene that regulates β-catenin activity"**

- **作者**: Firestein, R. et al.

- **摘要**: 该研究通过基因扩增分析发现CDK8在结直肠癌中显著扩增，并利用特异性CDK8抗体证实其过表达。实验表明CDK8通过增强β-catenin介导的转录活性促进肿瘤发生，提示其作为致癌基因的潜在治疗靶点。

2. **"MED12 regulates CDK8 kinase activity and promotes tumorigenesis"**

- **作者**: Galbraith, M.D. et al.

- **摘要**: 研究揭示了MED12蛋白对CDK8激酶活性的调控机制，使用CDK8抗体进行免疫共沉淀实验，证明MED12缺失会抑制CDK8活性，并影响癌基因相关信号通路，为靶向CDK8-MED12复合物的癌症治疗提供依据。

3. **"Discovery and characterization of a selective CDK8 inhibitor and its preclinical antitumor effects"**

- **作者**: Porter, D.C. et al.

- **摘要**: 本文报道了一种选择性CDK8小分子抑制剂的开发，通过CDK8抗体验证其在体外和体内实验中抑制肿瘤生长的效果，表明靶向CDK8可有效阻断Wnt/β-catenin等致癌信号通路，具有临床转化潜力。

(注：以上文献信息基于领域内典型研究方向模拟，实际引用时建议通过PubMed或学术数据库核实具体细节。)

背景信息

The CDK8 (Cyclin-Dependent Kinase 8) antibody is a key tool for studying the role of CDK8. a serine/threonine kinase within the Mediator complex, which regulates RNA polymerase II-dependent transcription. CDK8. along with its regulatory partners Cyclin C, MED12. and MED13. modulates gene expression by phosphoryrating transcription factors (e.g., STAT1. SMADs) and histone tails, influencing processes like cell cycle progression, oncogenesis, and stress responses. Dysregulation of CDK8 is linked to cancers (e.g., colorectal, breast) and developmental disorders, making it a potential therapeutic target.

CDK8 antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunohistochemistry to detect CDK8 expression, localization, and interactions. These antibodies help elucidate CDK8's context-dependent roles as either an oncogene or tumor suppressor. For example, CDK8 inhibitors are under investigation for cancer therapy, necessitating reliable antibodies for preclinical studies. Researchers must validate CDK8 antibodies for specificity, as some may cross-react with homologous kinases (e.g., CDK19). Advances in antibody development, including monoclonal and phospho-specific variants, continue to enhance precision in studying CDK8's dynamic regulatory mechanisms and clinical relevance.